Gushengtang Logs 42% Boost in Q1 Customer Visits
Gushengtang Holdings (HKG:2273) recorded around 1.1 million customer visits during the three months ended March 31, up 42.1% from the year-ago figure of 756,000 visits, a Thursday filing on the Hong K
On April 26, Gushengtang (02273.HK) spent HK$1.33 million to repurchase 29,600 shares
Gelonghui, April 26 | Gushengtang (02273.HK) announced that it spent HK$1.33 million to repurchase 29,600 shares on April 26.
The total number of visits to Gushengtang (02273.HK) customers in the first quarter was about 1.074,000, an increase of about 42.1% year-on-year
Gelonghui, April 25 | Gushengtang (02273.HK) announced that the total number of customer visits in the three months ended March 31, 2024 was about 1.074,000, an increase of about 42.1% over the same period in 2023 (about 756,000 customer visits). In the three months ended March 31, 2024, the total number of customer visits to the company's newly established medical institutions was about 74,000, accounting for 9.8% of the 42.1% increase in the number of patients treated above.
Are Robust Financials Driving The Recent Rally In Gushengtang Holdings Limited's (HKG:2273) Stock?
Most readers would already be aware that Gushengtang Holdings' (HKG:2273) stock increased significantly by 8.9% over the past week. Given that the market rewards strong financials in the long-term,
固生堂:2023年度報告
Gushengtang cancels 1,544,400 shares already purchased
Gushengtang (02273) announced that on April 19, 2024, the company cancelled 1,544,400 repurchased shares.
Goseido (02273.HK) cancelled 1.54 million shares on April 19
Gelonghui, April 19, 丨 Gushengtang (02273.HK) announced that on April 19, 2024, the company cancelled 1.54 million repurchased shares.
Gushengtang (02273) spent HK$5.2471 million to buy back 130,000 shares on April 16
Gushengtang (02273) announced that on April 16, 2024, the company spent HK$5.2471 million...
[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare
On April 15, Gushengtang (02273.HK) spent HK$5.74 million to buy back 140,000 shares
On April 15, Gelonghui (02273.HK) announced that on April 15, it spent HK$5.74 million to repurchase 140,000 shares at a price of HK$40.6-41.2 per share.
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Gushengtang (02273.HK) spent HK$2.98 million to buy back 70,000 shares on April 5
Gelonghui, April 5 | Gushengtang (02273.HK) announced that on April 5, it spent HK$2.98 million to repurchase 70,000 shares at a price of HK$42.2-43.2 per share.
Changes in Hong Kong stocks | Gushengtang (02273) rose nearly 5%, and healthcare solutions generated revenue increased by about 23 billion yuan, up 43% year-on-year
The Zhitong Finance App learned that Gushengtang (02273) rose nearly 5% and rose 4.95% at press time to HK$44.5, with a turnover of HK$18.87 million. According to the news, the company recently announced its 2023 results, with revenue of about 2,323 billion yuan, up 43% year on year; gross profit of about 700 million yuan, up 40.1% year on year; profit attributable to parent company owners of about 252 million yuan, up 39.45% year on year; basic profit per share. The announcement stated that the increase in revenue was mainly due to increased revenue from providing healthcare solutions. Increased revenue from providing healthcare solutions4
Zhitong Hong Kong Stock Repurchase Statistics|April 3
According to data from the Zhitong Finance App, Yongan International (00289), Skyworth Group (00751), Mobi Development (00947), Weiyuantang (00897), Qingke Venture (01945), Fuzhikang Group (02038), Tencent Holdings (00700), Tianfu (06868), Bairongyun-W (06608), Saijing Technology (00580), Gushengtang (02273), Yidu (International Holdings) (00259), Digital Telecom (00259) 00315), Beijing Holdings (00392), China Software International ( 00354), Sinopec
Gushengtang (02273.HK) spent HK$4.12 million to buy back 95,000 shares on April 2
Gelonghui, April 2 | Gushengtang (02273.HK) announced that on April 2, it spent HK$4.12 million to repurchase 95,000 shares at a price of HK$42.55-43.6 per share.
Huafu Securities: Target price of HK$57.88 for the “buy” rating for Gushengtang (02273)
The bank mentioned that Gushengtang's business layout continued to expand last year. As of 2023/12/31, the company owns and operates 56 medical institutions, covering 16 cities. During the reporting period, the company acquired 7 offline institutions and built 2 offline institutions of its own; on the online side, the company has now established cooperative relationships with various third-party online platforms.
Gushengtang Holdings Limited's (HKG:2273) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 39.2x Gushengtang Holdings Limited (HKG:2273) may be sending very bearish signals at the moment, given that almost half of all companies in Hong Kong have
Gushengtang Holdings' Net Profit Jumps in 2023
Gushengtang Holdings' (HKG:2273) net profit attributable to owners jumped to 252.2 million yuan in the full year 2023 from a restated net profit of 180.9 million yuan in the year prior, according to a
Gushengtang (02273) spent HK$21.835,800 to buy back 499,400 shares on March 28
According to the Zhitong Finance App, Gushengtang (02273) announced that on March 28, 2024, the company spent HK$21.835,800 to repurchase 49,400 shares at a repurchase price of HK$43.2-44.1 per share.
Understand the 2023 annual results highlights of Gushengtang (2273.HK)
On March 27, Gushengtang (2273.HK) announced the results for the year ended December 31, 2023. We will take you to understand the specific results in a chart.
No Data